Edwards Lifesciences stock popped late Thursday after the heart devices maker beat third-quarter profit expectations and kept ...

Edwards Lifesciences on Thursday forecast fourth-quarter sales below Wall Street estimates, hurt by softer demand and fierce ...

Edwards maintained its prior guidance for full-year sales growth of 8-10%, and expects Q4 sales of $1.33 billion to $1.39 ...

Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended Sept. 30, 2024. Highlights and Outlook ...

Wedgewood Partners, an investment management company, released its third-quarter 2024 investor letter. A copy of the letter ...

Pre-earnings options volume in Edwards Lifesciences (EW) is 1.4x normal with calls leading puts 10:9. Implied volatility suggests the market is ...

(RTTNews) - Edwards Lifesciences Corp. (EW) reported a profit for its third quarter that increased from last year The company's earnings came in at $362.1 million, or $0.61 per share. This compares ...

Looking at options history for Edwards Lifesciences EW we detected 14 trades. If we consider the specifics of each trade, it is accurate to state that 42% of the investors opened trades with bullish ...

After Losing Over $16 Billion Of Market Capitalization Edwards Lifesciences (EW) Faces Investor Class Action - Hagens Berman ...

IRVINE, Calif. (AP) — IRVINE, Calif. (AP) — Edwards Lifesciences Corp. (EW) on Thursday reported third-quarter earnings of $3.07 billion. On a per-share basis, the Irvine, California-based company ...

A total of 26 analyst ratings have been received for Edwards Lifesciences, with the consensus rating being Neutral. The average one-year price target stands at $77.69, suggesting a potential 12.2% ...

加利福尼亚州欧文市 - Edwards Lifesciences (NYSE:EW) 公布的第三季度盈利超过分析师预期，主要得益于其经导管二尖瓣和三尖瓣治疗（TMTT）业务的强劲增长。周四公布业绩后，该公司股价上涨4.19%。